Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.

Biotechnology

Abata Therapeutics

Abata Therapeutics' headquarters in Cambridge, MA, United States

John Trzupek

Ellen Cahir-McFarland

Sandy Lazzari

Matthias John

Fang Xia

Gerald Nepom

John Maraganore

Valerie Odegard

Shelley Chu

Michael Birnbaum

Diane Mathis

Daniel Reich

Abbie Celniker

Lorence Kim

Roland Martin

David Kaufman

Richard M. Ransohoff

Description

People (4)

David Kaufman

Fang Xia

Cj Ives

Sandy Lazzari

Jobs